Currently, a Phase I/II study of the rapidly manufactured (< 2 days) autologous CD19 CAR T-cell product (known as rapcabtagene autoleucel) in combination with ibrutinib in r/r CLL/SLL (NCT03960840) is ongoing. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.